Discounted Cash Flow
Kiniksa Pharmaceuticals International, Plc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $0 | $-1.5m | $-882.4k | — | $-0.01 |
| 2017 | $0 | $-64.9m (-4139.0%) | $-50.3m (-5599.2%) | — | $-35.85 (-358400.0%) |
| 2018 | $0 | $-103.2m (-59.1%) | $-86.3m (-71.6%) | — | $-3.49 (90.3%) |
| 2019 | $0 | $-161.9m (-56.8%) | $-161.6m (-87.2%) | — | $-2.99 (14.3%) |
| 2020 | $0 | $-161.4m (0.3%) | $-136.8m (15.3%) | — | $-2.61 (12.7%) |
| 2021 | $38.5m | $-157.9m (2.1%) | $-126.7m (7.4%) | -409.7% | $-2.30 (11.9%) |
| 2022 | $220.2m (471.2%) | $183.4m (216.1%) | $5.7m (104.5%) | 83.3% (120.3%) | $2.64 (214.8%) |
| 2023 | $270.3m (22.7%) | $14.1m (-92.3%) | $13.2m (131.0%) | 5.2% (-93.7%) | $0.20 (-92.4%) |
| 2024 | $423.2m (56.6%) | $-43.2m (-406.7%) | $25.4m (92.9%) | -10.2% (-295.8%) | $-0.60 (-400.0%) |
| 2025 | $677.6m (60.1%) | $59.0m (236.6%) | $136.4m (436.8%) | 8.7% (185.3%) | $0.80 (233.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.